Last updated: 2026-10-14 23:05:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Enliven Therapeutics, Inc. (ELVN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $39.27, with a market capitalization of $2.99B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.79 to $62.32. This page covers its latest market performance, valuation, price trends and company information.
$2.99B | |
$38.99 | |
$62.32 | |
$9.80 | |
$39.49 | |
1.08M | |
1.15M | |
-- | |
$62.32 | |
$14.79 | |
-- | |
-- |
Enliven Therapeutics, Inc. (ELVN) is trading at $39.28 in after-hours trading as of 2026-10-14 21:20:00, down 0.53% ($0.21) from the regular-session close of $39.49.
After-hours trading shows how investors are pricing ELVN after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Enliven Therapeutics, Inc. (ELVN) moved from $45.47 to $39.27, representing a decline of 13.63% ($6.20).
The stock traded between $38.39 and $46.94 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.24 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 51.5%
ELVN is currently trading at $39.27, placing it 51.5% of the way from its 52-week low of $14.79 to its 52-week high of $62.32. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 67 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Enliven Therapeutics, Inc. (ELVN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.